OncoMatch/Clinical Trials/NCT06149559
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Is NCT06149559 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies rozanolixizumab for generalized myasthenia gravis.
Treatment: rozanolixizumab — The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CHRNA1 autoantibody to acetylcholine receptor (AChR)
record confirming the presence of MG specific autoantibodies to acetylcholine receptor (AChR)
Required: MUSK autoantibody to muscle-specific kinase (MuSK)
record confirming the presence of MG specific autoantibodies to ... muscle-specific kinase (MuSK)
Disease stage
Required: Stage MGFA II, MGFA III, MGFA IVA (MGFA)
Excluded: Stage MGFA IVB, MGFA V
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IVa at Screening
Prior therapy
Must have received: conventional treatment for gMG (pyridostigmine, corticosteroids, immune suppressants)
has received existing conventional treatment(s) for gMG (eg, pyridostigmine, corticosteroids, and/or immune suppressants) prior to Screening
Cannot have received: thymectomy
Exception: allowed if >6 months prior to Screening
history of thymectomy within 6 months prior to Screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mg0006 50574 · Flower Mound, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify